Compare ESCA & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESCA | NYXH |
|---|---|---|
| Founded | 1922 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.1M | 190.6M |
| IPO Year | 1995 | 2021 |
| Metric | ESCA | NYXH |
|---|---|---|
| Price | $14.82 | $4.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | 11.1K | ★ 47.8K |
| Earning Date | 06-03-2026 | 01-01-0001 |
| Dividend Yield | ★ 4.02% | N/A |
| EPS Growth | ★ 30.99 | N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | ★ $180,541,000.00 | N/A |
| Revenue This Year | N/A | $97.32 |
| Revenue Next Year | $3.00 | $241.74 |
| P/E Ratio | $20.60 | ★ N/A |
| Revenue Growth | ★ 2.71 | N/A |
| 52 Week Low | $11.41 | $4.10 |
| 52 Week High | $16.99 | $11.87 |
| Indicator | ESCA | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 54.43 | 37.17 |
| Support Level | $13.99 | N/A |
| Resistance Level | $14.63 | $4.99 |
| Average True Range (ATR) | 0.31 | 0.32 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 55.36 | 7.97 |
Escalade Inc manufactures and distributes sporting goods for a varied range of activities. These sports include archery, table tennis, basketball goals, trampoline, play systems, fitness, game tables like hockey and soccer, billiards, darting and other outdoor games. These products are sold under the brand names like Goalrilla, Goalsetter, Woodplay, Silverback, Nodor, Rage, Child Life, among others. The geographic segments in which the company operates are North America, Europe and others out of which a substantial part of the revenue is generated from North America region.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.